Immedica Pharma acquisition of pegzilarginase assets from Aeglea
We advised Immedica on the transaction
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
BMS $35 million investment in Immatics
We advised Immatics on the private placement of ordinary shares
Centogene strategic collaboration with Lifera
We are advising Centogene on its joint venture with and convertible debt investment by Lifera
Noile-Immune Biotech ¥3.1 billion global IPO
The shares are listed on the Tokyo Stock Exchange
Oculis Holding $40.25 million debut equity offering
The shares are listed on the Nasdaq Global Market
Forbion European Acquisition combination with enGene
We are advising Forbion European Acquisition on its de-SPAC transaction
GSK exclusive licensing agreement with Scynexis
We advised GSK on the transaction
ACELYRIN $621 million IPO
The stock is listed on the Nasdaq Global Select Market
Kenvue $4.37 billion IPO
The carve-out of the former Johnson & Johnson consumer health business is the largest U.S. IPO since November 2021
Cellular Biomedicine Group CAR-T collaboration and license agreement with Janssen
We are advising Cellular Biomedicine Group on the transaction